



FOR IMMEDIATE RELEASE

TSX Venture Exchange: MDX

## **MedX Health Corp. and Melanoma Network of Canada announce strategic partnership: Collaborating on occupational health and safety offering for corporate Canada and their employees**

**MISSISSAUGA, ON, May 25, 2017** – MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce its ground-breaking partnership with the Melanoma Network of Canada (“MNC”). The MNC is a national organization that provides melanoma awareness and prevention information to the public, patient support and advocacy, and assists in efforts to target funding for-research. MedX and the MNC will collaborate to create a health and safety program that includes melanoma education and an onsite skin cancer screening program using MedX’s SIAscopy technology. This program will be marketed to Corporations, Life Insurance Companies and Government agencies.

“We are excited to be partnering with MedX. They have been tireless supporters of our efforts in educating Canadians about melanoma through our sun awareness and prevention campaigns,” said Alexa Cain, Executive Director of MNC. “This is a perfect fit. MedX’s superior SIAscopy technology allows for quick, painless examination of suspicious moles and lesions. Bringing skin cancer screening to Canadians through their workplace is an innovative approach to early detection,” she added.

According to MNC, if skin cancers were detected early, the benefit to the healthcare system would be significant with the potential of reducing insurance costs for employers.

The MNC says skin cancer is rising because of an aging population, the use of sun tanning beds by younger people, and exposure to harmful UV waves as more leisure time is spent outdoors without adequate sun protection. Melanoma is one of the 10 most common cancers diagnosed in Canada.

“MedX’s technology makes screening for skin cancer easy and accessible. Our goal is to make skin cancer screening as easy as getting a flu shot and this collaboration with MNC will allow us to reach many more Canadians,” said Robert von der Porten, President & CEO of MedX.

MedX’s SIAscope technology produces a dermoscopic image of a suspicious mole, as well as 4 additional images from 2 mm beneath the skin's surface. The scan is pain-free and the images enable a dermatologist to make a remote assessment of the individual’s suspicious mole.

## **About MedX**

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit [www.medxhealth.com](http://www.medxhealth.com).

## **About Melanoma Network of Canada**

Melanoma Network of Canada (MNC) provides support services, information and programs for individuals whose lives have been changed by melanoma. MNC provides the leading national voice for melanoma patients in Canada for better early detection and improved treatment access and works diligently to prevent more Canadians from developing melanoma and skin cancer through public awareness youth and adult education on sun safety. For more information, please visit [www.melanomanetwork.ca](http://www.melanomanetwork.ca).

### **Contacts:**

Rob von der Porten, President & CEO

**MedX Health Corp**

905-670-4428 ext 226

Alexa Cain, Executive Director

Melanoma Network of Canada

905.901.5121

1.877.560.8035 ext 102

### **Media Relations**

Deborah Thompson

[Deborah@dt-communications.ca](mailto:Deborah@dt-communications.ca)

416-918-9551